| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $2.9M | -64.3% |
| SG&A Expense | $4.8M | +12.4% |
| Operating Income | -$7.8M | +37.9% |
| Net Income | -$7.6M | +38.5% |
| EPS (Basic) | -$8.16 | -1.6% |
| EPS (Diluted) | -$8.16 | -1.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $7.5M | +137.9% |
| Total Assets | $7.9M | +122.5% |
| Total Liabilities | $1.6M | -16.8% |
| Stockholders' Equity | $6.2M | +298.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.8M | +30.5% |
| Financing Cash Flow | $12.1M | +76.0% |